Compare LSTA & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSTA | KTTA |
|---|---|---|
| Founded | 1980 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 18.1M |
| IPO Year | 2000 | 2021 |
| Metric | LSTA | KTTA |
|---|---|---|
| Price | $1.33 | $0.47 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 283.9K | 157.2K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.42 | ★ 77.07 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,283,868.00 | $486,559.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 56.90 | ★ 3130.37 |
| 52 Week Low | $0.99 | $0.28 |
| 52 Week High | $5.07 | $2.06 |
| Indicator | LSTA | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 36.98 |
| Support Level | $0.99 | $0.43 |
| Resistance Level | $2.06 | $0.52 |
| Average True Range (ATR) | 0.18 | 0.03 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 1.23 | 13.37 |
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.